ThE object of this study was to characterize the synthesis and metabolism of platelet activating factor (PAF) by intestinal mucosa subjected to ischaemia-reperfusion injury. Canine intestinal mucosa produced 16:0-PAF, 18:0-PAF, and high levels of the corresponding lyso-PAF metabolites. Three h of intestinal ischaemia and ischaemia followed by I h of reperfusion did not affect the synthesis or metabolism of PAF by intestinal mucosa. Intestinal mucosa elaborated a factor that rapidly hydrolyzes PAF to lyso-PAF. The observed hydrolysis rate was not altered by ischaemia or ischaemia and reperfusion. In conclusion, this study suggests that intestinal mucosa produces PAF and rapidly hydrolyzes PAF. The PAF synthesis and metabolism rates of intestinal mucosa is not altered by ischaemia reperfusion in this model under the imposed conditions.
Introduction
Intestinal ischaemia followed by reperfusion resuits in characteristic mucosal lesions. Increases in microvascular permeability with transvascular movement of fluid and macromolecules frequently occurs. Although the mechanisms of ischaemic damage are not completely understood, local inflammatory mediators have been implicated in the process. These mediators include oxygen radicals, 1 ," eicosanoids and platelet activating factor. 4, 5 Exogenous PAF increases intestinal capillary permeability and promotes leukocyte adhesion to the post-capillary venous endothelium. 6, 7 Ischaemia-induced changes in intestinal permeability are attenuated by Ginko biloba extracts which contain PAF receptor antagonist activity, 8 and synthetic PAF receptor antagonists reduce the histological evidence of ischaemic damage. Material 
Results
The production of 16:0 PAF, 18:0 PAF, 16:0 lyso-PAF, and 18:0 lyso-PAF by intestinal mucosa is shown in Fig. 1 . PAF synthesis was determined in normal mucosa, ischaemic mucosa, and mucosa subjected to ischaemia and reperfusion. Although synthesis of PAF and lyso-PAF was clearly measurable, no significant influence of ischaemia or reperfusion, relative to non-ischaemic levels was observed. Interestingly, statistically significantly higher (about 7-fold) amounts of the corresponding 2-1yso-PAF metabolite was detected in all mucosal tissue assayed. The signal attributable to the 18:1-PAF derivative was also monitored, but this material was not detected in any mucosal tissue samples. Clearly, intestinal mucosa produces two 1-O-alkyl species of PAF with the corresponding 2-1yso PAF metabolite being far more abundant (7-fold). Furthermore, synthesis of this mediator was not influenced by tissue ischaemia or reperfusion. Fig. 2 shows that intestinal mucosa liberates a factor that rapidly hydrolysis exogenous PAF to lyso-PAF. Incubation media that did not contain intestinal, mucosa (tissue blank) hydrolyzed PAF to < 5% indicating that the activity was derived from the tissue. This tissue-derived factor released into the incubation media is presumed to be the enzyme PAF acetyl hydrolase. These data also indicate that media derived from ischaemic tissue or from tissue after reperfusion hydrolyze PAF rapidly but not at a different rate than normal mucosa. These data are consistent with the PAF and lyso-PAF levels measured in normal and ischaemic intestinal mucosa (Fig. 1) . Lyso-PAF was more predominant than was PAF, and production rates of both PAF and lyso-PAF were independent of ischaemia and reperfusion. 
